SOURCE: StockCall

StockCall

February 02, 2011 08:24 ET

Equity Research on Valeant Pharmaceuticals International and Hospira Inc. -- Drug Delivery Space Up-in-Arms Over Generics

JOHANNESBURG, SOUTH AFRICA--(Marketwire - February 2, 2011) - www.stockcall.com/ offers investors comprehensive research on the drug delivery industry and has completed analytical research on Valeant Pharmaceuticals International (NYSE: VRX) and Hospira Inc. (NYSE: HSP). Register with us today at www.stockcall.com/ to have free access to these researches. 

In a patent intensive sector, it is no secret that any change in regulatory procedure involving patents will have widespread effects. In the Drug Delivery industry, generics have the ability to squash the revenues from massively profitable drugs. Valeant Pharmaceuticals International is an example of this as its income from drugs Diastat and Ribavirin have fallen off greatly since generic competition was introduced. A recent regulatory provision included in the health-care overhaul could greatly impact the patent rights of certain biotech companies. Valeant Pharmaceuticals International research report is accessible for free by registering today at www.stockcall.com/VRX020211.pdf.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the drug delivery industry can have easy and free access to our analyst research and opinions on Valeant Pharmaceuticals International and Hospira Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

Brand name drug makers are fighting over regulation that gives a twelve year exclusivity right to the maker of a biotech drug. They are arguing that this twelve year period should be renewed if the company makes safety or potency improvements. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Companies within the sector such as Hospira Inc. which make generic versions of drugs are worried that this interpretation of the law will enable brand-name makers to perpetually retain exclusivity through small tweaks to their products. The outcome of the FDA's interpretation will greatly impact companies like Hospira regardless of which way it goes. Hospira Inc. research report is available for free by signing up now at www.stockcall.com/HSP020211.pdf

Earnings calendar for this space shows Hospira Inc. and Valeant Pharmaceuticals International releasing their financial readings on February 2nd and February 21st respectively.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information